These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10447142)

  • 1. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
    Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
    Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis.
    Saad A; Young MR; Studtmann AE; Autry EB; Schadler A; Beckman EJ; Gardner BM; Wurth MA; Kuhn RJ
    Pediatr Pulmonol; 2020 Dec; 55(12):3384-3390. PubMed ID: 32910553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
    Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
    Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
    Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
    [No Abstract]   [Full Text] [Related]  

  • 7. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
    Ochs MA; Dillman NO; Caverly LJ; Chaffee VD
    Pediatr Pulmonol; 2021 Dec; 56(12):3634-3643. PubMed ID: 33983680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Møller NE; Høiby N
    Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetany in a child with AIDS receiving intravenous tobramycin.
    Slayton W; Anstine D; Lakhdir F; Sleasman J; Neiberger R
    South Med J; 1996 Nov; 89(11):1108-10. PubMed ID: 8903300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
    Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
    J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
    Smyth AR
    J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
    [No Abstract]   [Full Text] [Related]  

  • 17. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
    Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
    Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.